Repare Therapeutics Inc (RPTX)

04:55 AM

What drives Repare Therapeutics Inc. stock priceExponential return rates - jammulinksnews.com

04:55 AM

Jul 22, 2025

What analysts say about Repare Therapeutics Inc. stockRecord-breaking gains - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

Why Repare Therapeutics Inc. stock attracts strong analyst attentionFree Access to Community - Newser

Jul 22, 2025

Jul 22, 2025

Repare Therapeutics Inc. Stock Analysis and ForecastUnprecedented growth rates - jammulinksnews.com

Jul 22, 2025

Jul 19, 2025

Is Repare Therapeutics Inc. a good long term investmentOutstanding capital returns - jammulinksnews.com

Jul 19, 2025

Jul 19, 2025

what makes repare therapeutics inc. stock price move sharplyLow Risk Profit Ideas - Newser

Jul 19, 2025

Jul 18, 2025

Layoff Tracker: Following Challenges With DMD Therapy, Sarepta Will Cut 500 Employees - BioSpace

Jul 18, 2025

Jul 16, 2025

Repare Therapeutics Jumps 15% After $10M Licensing Deal With Debiopharm - Yahoo Finance

Jul 16, 2025

Jul 16, 2025

How Repare Therapeutics Inc. stock performs during market volatilityBig Profit Small Risk Alerts - Newser

Jul 16, 2025

Jul 16, 2025

Repare Therapeutics Jumps 15% After $10M Licensing Deal With Deb - GuruFocus

Jul 16, 2025

Jul 16, 2025

Repare Therapeutics Licenses Lunresertib to Debiopharm for Worldwide Development. - AInvest

Jul 16, 2025

Jul 16, 2025

Deal Watch: Debiopharm Takes On Precision Oncology Drug From Repare Collab - insights.citeline.com

Jul 16, 2025

Jul 16, 2025

Repare inks licensing deal with Debiopharm for lunresertib - The Pharma Letter

Jul 16, 2025

Jul 16, 2025

Repare Therapeutics Jumps After Hours On $267M Global Licensing Deal With Debiopharm; Retail Traders Rush In - Stocktwits

Jul 16, 2025

Jul 16, 2025

how repare therapeutics inc. stock performs during market volatilityFast Moving Stock Alerts - Newser

Jul 16, 2025

Jul 16, 2025

Repare Therapeutics' Lunresertib Deal: A Strategic Pivot to Unlock Oncology Potential and Near-Term Catalysts - AInvest

Jul 16, 2025

Jul 16, 2025

Repare Therapeutics stock surges after $10M licensing deal with Debiopharm By Investing.com - Investing.com South Africa

Jul 16, 2025

Jul 15, 2025

What makes Repare Therapeutics Inc. stock price move sharplyHigh Reward Risk Balanced Trading - Newser

Jul 15, 2025

Jul 15, 2025

Repare Therapeutics stock surges after $10M licensing deal with Debiopharm - Investing.com Nigeria

Jul 15, 2025

Jul 15, 2025

Repare Therapeutics Inc. Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib - MarketScreener

Jul 15, 2025

Jul 15, 2025

Repare Therapeutics (RPTX) Secures Global Licensing Deal with Debiopharm | RPTX Stock News - GuruFocus

Jul 15, 2025

Jul 15, 2025

Repare Therapeutics enters exclusive worldwide licensing agreement with Debiopharm for Lunresertib - MarketScreener

Jul 15, 2025

Jul 15, 2025

Repare Therapeutics licenses PKMYT1 inhibitor to Debiopharm for $10 million - Investing.com Nigeria

Jul 15, 2025

Jul 15, 2025

Repare Therapeutics jumps on cancer drug licensing deal - TradingView

Jul 15, 2025

Jul 15, 2025

Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib | RPTX Stock News - GuruFocus

Jul 15, 2025

Jul 15, 2025

Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib - Business Wire

Jul 15, 2025

Jul 07, 2025

Repare Therapeutics (NASDAQ:RPTX) Trading Down 4.9%What's Next? - MarketBeat

Jul 07, 2025

Jul 04, 2025

Repare Therapeutics (NASDAQ:RPTX) Stock Price Down 4.9% – Should You Sell? - Defense World

Jul 04, 2025

Jun 25, 2025

Repare Therapeutics Out-Licenses Discovery Platforms to DCx Biotherapeutics in Strategic Deal - Insider Monkey

Jun 25, 2025

Jun 25, 2025

Is Repare Therapeutics, Inc. overvalued or undervalued? - MarketsMojo

Jun 25, 2025